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 26 
Abstract 27 
Context: Treatment of congenital adrenal hyperplasia (CAH) is suboptimal. Inadequate suppression of 28 
androgens and glucocorticoid excess are common and current glucocorticoid formulations cannot replace 29 
the cortisol circadian rhythm.  30 
Objectives: The primary objective was to characterize the pharmacokinetic profile of Chronocort
®
, a 31 
modified-release hydrocortisone formulation, in adults with CAH. Secondary objectives included 32 
examining disease control following 6 months of Chronocort
®
 with dose titration.  33 
 34 
Design, Setting and Patients: Sixteen adults (8 females) with classic CAH participated in an open label, 35 
non-randomized, Phase 2 study at the National Institutes of Health Clinical Center. 24-hour blood 36 
sampling was performed on conventional glucocorticoids and following 6 months of Chronocort
®
. 37 
Chronocort
®
 was initiated at 10mg (0700h) and 20mg (2300h). Dose titration was performed based on 38 
androstenedione and 17-hydroxyprogresterone (17-OHP) levels and clinical symptomatology.  39 
Main Outcome Measures: Cortisol pharmacokinetics of Chronocort
®
 and biomarkers of CAH control 40 
(androstenedione and 17-OHP).  41 
Results:  In CAH patients, Chronocort
®
 cortisol profiles were similar to physiologic cortisol secretion. 42 
Compared to conventional therapy, 6 months of Chronocort
®
 resulted in a decrease in hydrocortisone 43 
dose equivalent (28 ± 11.8 vs. 25.9 ± 7.1mg/day), with lower 24-hour (P = 0.004), morning (0700h - 44 
1500h; P = 0.002), and afternoon (1500h - 2300h; P = 0.011) androstenedione area under the curve 45 
(AUC) and lower 24-hour (P = 0.023) and morning (0700h - 1500h; P = 0.02) 17-OHP AUC. 46 
Conclusions: Twice daily Chronocort
®
 approximates physiologic cortisol secretion, and was well 47 
tolerated and effective in controlling androgen excess in adults with CAH. This novel hydrocortisone 48 
formulation represents a new treatment approach for patients with CAH. 49 
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 50 
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is characterized by cortisol and 51 
aldosterone deficiency and androgen excess (1). Goals of treatment are to replace deficient hormones and 52 
control excess androgen, while avoiding the adverse effects of exogenous glucocorticoid excess. 53 
Physicians caring for CAH patients often face management challenges. Thrice daily immediate-release 54 
short-acting hydrocortisone is the recommended therapy in growing children (2). However, there are no 55 
standard clinical guidelines for glucocorticoid therapy in adults. Several regimens using short or long 56 
acting glucocorticoid formulations are commonly used in practice, given once to thrice daily as a fixed, or 57 
weight adjusted-dose (3-5). 58 
In addition to the lack of management consensus, it is difficult to achieve satisfactory outcome with 59 
conventional glucocorticoid formulations (6). These regimens are suboptimal as they cannot replace the 60 
normal cortisol circadian rhythm, and inadequate suppression of adrenal androgens and glucocorticoid 61 
excess are common (3,7). New hydrocortisone formulations are being produced. Plenadren
®
, marketed in 62 
Europe, is an immediate-release tablet with sustained-release hydrocortisone core taken first thing in the 63 
morning and provides once daily treatment but does not address the overnight rise in adrenocorticotrophic 64 
hormone(ACTH) (8). Chronocort
®
, a modified-release formulation of hydrocortisone in clinical 65 
development, aims to mimic the cortisol circadian rhythm and address the overnight ACTH rise driving 66 
the increase in androgens in CAH (9).  67 
We previously compared conventional immediate-release hydrocortisone administered thrice daily (10, 5 68 
and 15mg) to a pilot tablet modified-release hydrocortisone formulation (30mg at night) (Phoqus 69 
pharmaceuticals, UK) (10). This pilot modified-release hydrocortisone tablet was able to achieve 70 
physiologic cortisol levels and good control of ACTH and androgens overnight and in the early morning, 71 
but failed to provide adequate cortisol in the afternoon and evening leading to a rise in adrenal androgens. 72 
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Pharmacokinetic modeling suggested twice daily dosing would achieve better hormonal control, but 73 
further studies using this formulation were not possible due to manufacturing issues (11).  74 
To address this shortcoming, Chronocort
®
, a novel modified-release hydrocortisone formulation using 75 
scalable technology was developed (Diurnal Ltd, UK).  This new multi-particulate formulation has an 76 
enteric coat which has a pH trigger of 6.8, allowing small bowel dissolution. Phase 1 pharmacokinetic 77 
analysis showed that a twice daily regimen (10mg at 0700h and 20mg at 2300h) approximated 78 
physiologic cortisol rhythm (12). 79 
The aim of this study was to evaluate the pharmacokinetics of Chronocort
®
 in adults with CAH and test 80 
the hypothesis that providing near-physiologic cortisol replacement will improve control of androgenic 81 
precursors - androstenedione and 17-hydroxyprogresterone (17-OHP).   82 
 83 
Patients and Methods 84 
Patients 85 
Sixteen adult patients (8 females) with classic CAH participated in this open label, single center, phase 2 86 
study (www.clinicaltrials.gov identifier no. NCT01735617). Diagnosis of classic 21-hydroxylase 87 
deficiency was established based on medical records and genotype (13). All patients were on stable 88 
glucocorticoid and mineralocorticoid dosage for ≥ 3 months, in good general health and had laboratory 89 
evaluation within 12weeks of enrollment with plasma renin activity (PRA) < 1.5 times the upper normal 90 
range. Exclusion criteria included pregnancy, lactation, taking spironolactone or glucocorticoids (oral, 91 
inhaled or nasal) apart from treatment of CAH, significant medical or psychiatric illness, receiving 92 
medications that induce hepatic enzymes or interfere with glucocorticoid metabolism, history of bilateral 93 
adrenalectomy, or participation in a clinical trial within 3 months. 94 
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The study was approved by Eunice Kennedy Shriver National Institute of Child Health and Human 95 
Development Institutional Review Board. All patients provided written informed consent.  96 
 97 
Study Design 98 
The primary objective was to characterize the pharmacokinetic profile of short-term Chronocort
®
 99 
treatment in adults with CAH. Secondary objectives included examining the effect of Chronocort
®
 on 100 
hormone control following 6 months of dose titration.  101 
Patients were screened for eligibility up to 12 weeks prior to the first visit. All patients were admitted to 102 
the National Institutes of Health (NIH) Clinical Center every 2-months for a total of 6 months of 103 
treatment (Figure 1). Prior to Chronocort
® 
administration at visit 1, a 24-hour hormonal profile (2300h - 104 
2300h, 2-hourly) was obtained while on conventional therapy.  105 
Patients received their last dose of conventional therapy until 2300 of Day #2 and were started on twice 106 
daily Chronocort
®
 (2300h: 20mg; 0700h: 10mg) following completion of sampling on conventional 107 
therapy. This initial starting dose was chosen based on data from a prior Phase 1 study in healthy subjects 108 
(12). On Day #4 (48 hours post-dose initiation), 24-hour (2300h - 2300h) serial sampling (2-hourly from 109 
2300h - 0500h; 1-hourly from 0600h - 1600h and 2-hourly from 1700h - 2300h) was performed to 110 
evaluate Chronocort
® 
pharmacokinetics. 2-hourly serum samples (2300h - 2300h) were also drawn to 111 
evaluate ACTH, androstenedione and 17-OHP. Serial sampling was repeated after two, four and six 112 
months. Telephone contact was made within 2-weeks of each visit for dose adjustments and adverse event 113 
monitoring. After 6-months of Chronocort
®
 treatment, patients were discharged to home on their prior 114 
conventional regimen with telephone follow-up.  115 
 116 
Body composition was measured by Dual Energy X-ray Absorptiometry (DXA) prior to study medication 117 
administration at visit 1 and at the end of the study. Following breakfast at every visit, four questionnaires 118 
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were administered to assess fatigue (MAF, Multidimensional Assessment of Fatigue), health-related 119 
quality-of-life (SF-36, AddiQoL) and signs and symptoms of adrenal insufficiency.  120 
 121 
Study medication and dose modification 122 
Chronocort
®
, a modified-release capsule formulation of hydrocortisone, consists of uniform multi-123 
particulate beads which have an inert core, a hydrocortisone drug layer, and a delayed-release enteric 124 
outer coat (12). Chronocort
®
 was designed to mimic physiologic cortisol circadian rhythm through a 125 
delayed-release and sustained absorption profile of hydrocortisone after administration.  Chronocort
®
 was 126 
available in 20mg, 10mg, and 5mg capsules for this study.   127 
Dose adjustments were made in 5mg increments based on clinical symptoms of adrenal insufficiency or 128 
cortisol excess, and androstenedione and 17-OHP levels. Hormone levels obtained between 0100h and 129 
0900h and between 1100h and 1900h were considered to reflect the 2300h and the 0700h Chronocort
®
 130 
doses respectively. Dose adjustments were made if three or more of the 5 sample times showed out of 131 
range values for androstenedione and 17-OHP.  Optimal androstenedione levels were based on the normal 132 
range (men: 40-150, women: 30-200 ng/dL); 17-OHP levels were categorized optimal: 300-1200 ng/dL; 133 
suppressed: ≤ 300 ng/dL; elevated: ≥ 1200 ng/dL. 134 
When androstenedione and 17-OHP showed inconsistent trends, androstenedione took precedence in 135 
directing dose adjustment  since androstenedione levels are less variable (6). Daily Chronocort
®
 dosage 136 
was not to exceed 50mg or be less than 10mg. Dose adjustments were made within 2-weeks following 137 
visits by telephone. Patients were re-contacted within 1-week after each dose change.  138 
Compliance was assessed at each visit by accounting for number of capsules dispensed and number 139 
returned.  140 
 141 
Hormonal assays 142 
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Serum concentrations of cortisol (Simbec Research Limited, UK), 17-OHP and androstenedione (Mayo 143 
Medical Laboratories, Rochester, MN) were determined by high-performance liquid chromatography-144 
tandem mass spectrometry (LC-MS/MS). The cortisol assay had an analytical sensitivity of 0.05 µg/dL, 145 
inter-assay coefficient of variation (CV) of 2.6%, 4.5%, 2.4%, intra-assay CV of 3.7%, 1.1%, 1.9% at 146 
mean concentration of 0.8, 7.9 and 19.7 µg/dL respectively. The androstenedione assay had a sensitivity 147 
of 15 ng/dL, inter-assay CV of 7.9%, 7.2%, 8.7%, intra-assay CV of 13.9%, 5.9%, 2.6% at mean 148 
concentration of 112, 916 and 2281 ng/dL respectively and normal range of 40-150 ng/dL for males and 149 
30-200 ng/dL for females. The 17-OHP assay had an analytical sensitivity of 40 ng/dL, inter-assay CV of 150 
9.7%, 8.7%, 6.8%, intra-assay CV of 6.8%, 2.9%, 4.4% with a mean concentration of 111, 751 and 2006 151 
ng/dL respectively and normal range of ≤ 220 ng/dL for males and ≤ 285 ng/dL for females. 152 
Plasma ACTH was measured using a chemiluminescence immunoassay on Siemens Immulite 2000 XPi 153 
analyzer (NIH Clinical Center), with a sensitivity of 5 pg/mL, intra- and inter-assay CVs of 2.5% and 154 
3.6% respectively, and normal range of 0 - 46 pg/mL.  155 
 156 
Statistical analyses 157 
Data are presented as mean ± SD, unless otherwise indicated, and were analyzed using SAS v9.2 (SAS 158 
Institute, Inc, Cary, NC). All P values were two sided and < 0.05 was considered significant. 159 
Pharmacokinetic parameters for cortisol were calculated via non-compartmental analysis using Phoenix 160 
WinNonlin software (v6.3, Pharsight Corp., Mountain View, CA). The area under the curve (AUC) was 161 
computed using the linear-up, log-down trapezoidal rule for 24-hour (2300h - 2300h) and three 8-h time 162 
intervals (night: 2300h - 0700h; morning: 0700h - 1500h; afternoon: 1500h - 2300h) chosen to 163 
approximate physiologic periods of low, high and intermediate cortisol respectively. Peak concentration 164 
(Cmax) and time to peak concentration (Tmax) were determined using actual collection time-points. 24-hour 165 
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hormonal exposure was also evaluated based on the number of time-points that androgens were within 166 
elevated, optimal and suppressed ranges according to the categorization used for dose adjustments.  167 
Pharmacokinetic  parameters from this Phase 2 study were compared to prior Phase I study results in 168 
healthy volunteers  and  to cortisol profiles (using LC-MS/MS,) obtained in healthy controls not receiving 169 
any medication (n = 28) who underwent every 20min cortisol sampling over 24-hours as an 170 
approximation of normal circadian rhythm (12,14).  171 
 172 
SF-36 score was computed using SF-36v2 OptumInsight software as norm-based score, which employs a 173 
linear T-score transformation with mean of  50 and standard deviation of 10 (15). AddiQoL, a disease 174 
specific questionnaire developed for patients with adrenal insufficiency, has scores ranging from 30 175 
(worst possible) to 120 (best possible) (16). Global Fatigue Index (GFI) score was calculated using the 176 
MAF data and GFI scores range from 1 (no fatigue) to 50 (severe fatigue) (17).   177 
 178 
Depending on the data distribution, parametric (paired t-test) and non-parametric (Wilcoxon signed rank) 179 
tests were used to compare changes in AUCs, biomarkers and metabolic indices from baseline 180 
(conventional treatment) to 6-months of Chronocort
®
 therapy.  Categorical data between these intervals 181 
were compared using McNemar’s test.   182 
 183 
Results 184 
Twenty one patients were screened. Four patients failed to meet the inclusion criteria for PRA level and 185 
one patient was eligible but chose not to participate due to time constraints. Sixteen adults (8 females; 186 
median age: 24 years, range 18 - 60 years) with classic CAH (12 salt-wasting, 4 simple virilizing) 187 
participated. Patients were on a variety of glucocorticoid regimens (Table 1).  188 
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Medication accountability revealed that one patient was noncompliant with taking the study medication. 189 
Results were similar when analyses were repeated excluding this patient. At study completion, 75% of 190 
patients expressed an interest in continuing Chronocort
®
 if it were available. 191 
 192 
Pharmacokinetic Profile of Chronocort
®
  193 
The cortisol pharmacokinetic profile 48-hours post Chronocort
®
  initiation and following 6 months of 194 
therapy was similar to the normal circadian rhythm of cortisol observed in healthy subjects and the 195 
pharmacokinetic  profile of Chronocort
®
 observed in a Phase 1 study (Table 2) (12,14).   196 
Ten patients required Chronocort
®
 dose adjustments (decrease in 8, increase in 2) resulting in an overall 197 
decrease in glucocorticoid dose (glucocorticoid equivalent dose: conventional vs. 6 months: 28 ± 11.8 vs. 198 
25.9 ± 7.1mg/day). After 6 months of Chronocort
®
, there was no evidence of dose accumulation or 199 
nonlinear pharmacokinetics.  Overall exposure to cortisol (AUC) over 24-hours was similar following the 200 
first Chronocort
®
 dose and at 6 months (dose-normalized to 10 mg). However, peak cortisol levels were 201 
lower by approximately 10% at 6 month therapy (90% CI, 0.742 - 1.057), which was expected due to 202 
reduced doses following dose titration. 203 
 204 
Biomarkers of Disease Control 205 
On conventional therapy, ACTH levels began to rise at 0500h, plateaued between 0700h - 1500h, and 206 
declined after 1700h. 6 months Chronocort
® 
therapy resulted in lower ACTH levels throughout the day; 207 
however changes in ACTH were not significant (Figure 2).  208 
The majority of patients had elevated androstenedione and 17-OHP during the day while receiving 209 
conventional therapy. In comparison to baseline, androstenedione at 6 months showed a decrease in the 210 
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percent of time-points with elevated levels (33.7% vs. 12.0%, P < 0.0001) and a higher percent of time-211 
points in the normal range (55.8% vs. 73.1%, P <0.0001). Likewise compared to baseline, 17-OHP at 6 212 
months showed a decrease in the percent of timepoints with elevated levels (33.2% vs. 12.0%, P <0.0001) 213 
and an increase in the number of timepoints in the suppressed range (46.2% vs. 69.2%, P <0.0001). In 214 
fact, the majority (59%) of patients had 17-OHP values in the normal range (males: 40-220 ng/dL, 215 
females: 40-285 ng/dL) following 6 months of Chronocort
®
 therapy. 216 
Similarly, at 6 months, Chronocort
®
 resulted in lower 24-hour (P = 0.003), morning (0700h - 1500h; P = 217 
0.0008) and afternoon (1500h - 2300h; P = 0.009) AUC androstenedione and lower 24-hour (P = 0.021) 218 
and morning (0700h - 1500h; P = 0.018) AUC 17-OHP compared to conventional therapy.  219 
 220 
Disease related metabolic indices and quality-of-life estimates 221 
Following 6 months of Chronocort
®
: there were no significant changes in body mass index (BMI) but 222 
there was an increase in lean mass (P = 0.003); homeostasis model assessment-estimated insulin 223 
resistance (HOMA-IR) measured in the morning (2300h – 0700h) increased (1.91 ± 0.7 vs. 2.98 ± 1.7; P 224 
= 0.02); and the bone turnover marker osteocalcin, increased (P = 0.01) (Table 3). 225 
 226 
Sex differences were observed in some measurements of body composition. Although body composition 227 
showed an overall increase in lean mass (P = 0.003) and no changes in fat mass, subgroup analysis 228 
revealed that an increase in lean mass occurred in females only (P = 0.006) and males experienced a 229 
decrease in fat mass (P = 0.036). Whole body bone mineral density (BMD) showed a slight decrease (P = 230 
0.007), and subgroup analysis by sex showed a decrease in BMD in females only (P = 0.015) (Table 3). 231 
 232 
11 
 
No significant changes were noted in quality-of-life or fatigue (baseline vs. 6 months: SF-36: 54.2 ± 4.6 233 
vs. 53.7 ± 5.5; AddiQoL: 96.1 ± 10.9 vs. 97.4 ± 12.5; GFI: 14.3 ± 8.8 vs. 12.6 ± 9.3.  Of note, at baseline, 234 
mean SF-36 score across all domains was greater than 50, the mean of a healthy population (15). 235 
Similarly, AddiQoL and GFI scores were similar to a healthy population (16,17) .  236 
 237 
Adverse Events 238 
Chronocort
®
 was well tolerated. No serious adverse events occurred. Common short-term adverse events 239 
resolved and may have been associated with changes in glucocorticoid medication and/or the frequent 240 
blood sampling (Table 4). Six patients received stress dosing for acute viral illnesses of short duration. 241 
Two patients received stress dosing related to incidental surgical diagnosis and treatment (inguinal hernia, 242 
benign breast nodule). One patient experienced symptoms of adrenal insufficiency one week after starting 243 
the study and received stress dosing for a few days followed by an increase in Chronocort
®
 dose. One 244 
patient was diagnosed with tenosynovitis and one patient had worsening of trigger finger.  245 
Three patients had unexpected carpal tunnel syndrome, but two had a prior history. In one patient, 246 
symptoms self-resolved while still receiving Chronocort
®
.  The other two patients had symptomatic 247 
improvement with wrist splints. Changes in PRA were not observed. 248 
 249 
Discussion 250 
Our study is the first to demonstrate that it is possible to safely replace cortisol in a near physiologic 251 
manner using Chronocort
®
, an oral modified-release hydrocortisone formulation, in patients with CAH. 252 
This novel hydrocortisone formulation was well tolerated and effective in controlling androgen excess in 253 
adults with CAH when administered twice daily.  254 
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Chronocort
®
 is a multi-particulate modified-release capsule formulation of hydrocortisone, developed in 255 
attempt to overcome the challenges observed with conventional glucocorticoid therapy, such as inability 256 
to adequately control androgen secretion without the complications of supraphysiologic glucocorticoids 257 
(12). At baseline, while receiving conventional glucocorticoid therapy, 24-hour sampling revealed 258 
inadequate androgen control throughout the day in the majority of our patients, despite receiving long-259 
acting glucocorticoids. Although all of our CAH patients were on stable glucocorticoid doses for at least 260 
three months prior to study entry, inclusion criteria was not based on level of hormonal control.  Overall, 261 
our patients tended to have mildly elevated androgens on their conventional treatment, none were grossly 262 
over treated and none had hypothalamic-pituitary-adrenal axis suppression. Large cohort studies report 263 
that only about one third of adult patients with classic CAH have hormones within target ranges (3,18).    264 
Based on the data obtained in our study of classic CAH patients, Chronocort
®
 provides a stable peak to 265 
trough ratio of plasma cortisol concentrations that more closely mimics the normal circadian rhythm over 266 
a 24 hour period than conventional glucocorticoid replacement therapy. In particular, overnight cortisol 267 
rise (2300h - 0700h) and cortisol peak after awakening into the early afternoon (0700h - 1500h) had the 268 
most confluence with estimated physiologic cortisol secretion.  However, even with the twice daily 269 
regimen of Chronocort
®
, cortisol levels were low in the evening hours but the ACTH and androgen levels 270 
remained in an acceptable range and all patients exhibited persistence of an endogenous diurnal variation 271 
in their hormone levels. This supports the concept that less cortisol replacement is needed at this time of 272 
the day as naturally cortisol and ACTH levels are low (10,19,20).   273 
As the cortisol profile approximated physiologic cortisol secretion, Chronocort
®
 therapy effectively 274 
controlled the androgen excess characteristic of CAH. Compared to conventional therapy at baseline, 275 
Chronocort
®
 at 6 months showed improved serial androstenedione levels with lower 24-hour, morning 276 
and afternoon androstenedione and improved 17-OHP levels over 24 hours and in the morning. 277 
Interestingly the majority of 17-OHP levels were within the normal range, rather than in the mildly 278 
elevated range typically used for management (3,21). Single time-point morning androgen measurement 279 
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is frequently used for monitoring treatment in CAH (22). An advantage of our study was our ability to 280 
perform 24 hour serial sampling and this lowering of androgens observed throughout the day was 281 
achieved with lower average daily glucocorticoid doses.  282 
Our findings need to be considered within the context of the population of patients being studied and may 283 
be confounded by the multiple hormonal imbalances characteristic of CAH.  On Chronocort
®
, there was a 284 
decrease in overall glucocorticoid dose based on hydrocortisone dose equivalency, increase in lean body 285 
mass, decrease in fat mass (males only), and insulin resistance assessed by morning HOMA-IR increased. 286 
The increase in HOMA-IR was observed after the first dose of Chronocort
®
 and therefore is unlikely to 287 
reflect a change in body composition and might be due to a rise in early morning cortisol which does not 288 
occur with conventional glucocorticoid therapy. In healthy individuals insulin sensitivity falls before 289 
awakening associated with the physiological cortisol increase. Patients with adrenal insufficiency on 290 
hydrocortisone have low concentrations of metabolic fuels throughout the night, related to decreased 291 
overnight cortisol levels, and this might play a role in non-specific symptoms such as fatigue, early 292 
morning headache, and risk of hypoglycemia (23).  Exogenous glucocorticoids in pharmacologic doses 293 
have negative effects on the bone and decrease osteocalcin, a marker of bone formation (24).We observed 294 
an increase in osteocalcin reflecting lower glucocorticoid exposure during 6months of Chronocort
®
 295 
therapy. Conversely, we observed a slight decrease in whole body BMD, significant in females only.  296 
This finding is possibly due to a decrease in androgen exposure. Region specific BMD changes were not 297 
assessed. Future studies of Chronocort
®
 therapy in CAH patients should involve more detailed 298 
assessments of metabolic parameters and BMD. 299 
Patients with CAH have increased morbidity which in part is due to the limitations of current available 300 
glucocorticoid therapy (3,7,25-27).   As a result, novel therapies are being developed and studied by our 301 
group and others in an attempt to improve patient outcomes. (10,28,29). Short-term proof of concept 302 
studies and case reports have demonstrated promising results using continuous subcutaneous 303 
hydrocortisone infusion to achieve circadian cortisol replacement in CAH patients (28,30-32). In patients 304 
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with primary autoimmune adrenal insufficiency, once daily Plenadren
®
, the dual-release hydrocortisone, 305 
achieved normal morning cortisol levels but resulted in lower cortisol exposure over 24 hours and lack of 306 
normalization of early morning cortisol levels prior to awakening (33).  Thus it is doubtful that this type 307 
of hydrocortisone formulation would improve androgen excess in CAH patients because it does not 308 
provide overnight cortisol replacement. In contrast, the pharmacokinetic profile of cortisol on twice daily 309 
Chronocort
®
 showed good 24hour bioavailability resulting in lowering androgens in CAH patients.  310 
Although Chronocort
®
 overall achieved a near-physiological 24-hour cortisol profile, cortisol secretion 311 
exhibits a distinct circadian and ultradian rhythm which is influenced by the sleep-wake cycle and cannot 312 
be replicated with oral glucocorticoid replacement (11,34,35). The clinical significance of this is 313 
unknown.  The hypothalamic-pituitary axis has a significant role in the sleep-wake cycle (36,37), and a 314 
subset of our patients experienced sleep disturbances while receiving Chronocort
®
.
 
 Dose adjustments 315 
helped with early awakening in both patients but complaints of odd dreams persisted in one patient. 316 
Qualitative or quantitative assessments of sleep were not part of our study. We did not find any changes 317 
in quality-of-life, which was not surprising given the small sample size, short study duration and 318 
relatively normal baseline quality-of-life scores. 319 
There were no serious adverse events. Three patients had the unexpected adverse event of carpal tunnel 320 
syndrome. Two of these patients had a history of similar complaints in the past. The etiology of these 321 
three cases of median nerve entrapment syndrome is not clear. Although increased mineralocorticoid 322 
activity of Chronocort
®
 compared to pre-study treatments (prednisone, dexamethasone) is a possibility, all 323 
three patients were receiving fludrocortisone and no changes were seen in PRA.  324 
In addition to the small sample size, our study had a few important limitations.  First, the study was an 325 
open label, non-randomized design. Although majority of patients were being followed at the NIH prior 326 
to study enrollment and were known to be compliant on their conventional medication, it is possible that 327 
improved compliance occurred secondary to the close scrutiny characteristic of being enrolled in a 328 
15 
 
clinical trial. Moreover, an additional potential advantage during Chronocort
®
 therapy was the frequent 329 
dose adjustments to optimize treatment.  These potential biases are due to the nonrandomized study 330 
design. Second, although the study design allowed dosage adjustments, the options were limited as the 331 
smallest available dose was 5mg. Having smaller dose formulations would allow for more flexible and 332 
precise dose adjustments.  333 
It is anticipated that the ability of Chronocort
®
 therapy to mitigate the drastic fluctuations in cortisol 334 
levels observed with conventional glucocorticoid therapy while more closely mirroring physiologic 335 
diurnal variation will result in improved patient outcome. This newly-developed modified-release oral 336 
hydrocortisone formulation regimen given as a twice daily dosing represents a new treatment approach 337 
for patients with CAH.  Further studies, and studies including children, are necessary to determine the 338 
long-term outcomes of Chronocort
®
 therapy. 339 
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